6-isopropyl-3,4-dihydro-2H-pyran | 16765-49-4

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 6-isopropyl-3,4-dihydro-2H-pyran
• 英文别名: 6-propan-2-yl-3,4-dihydro-2H-pyran
• CAS: 16765-49-4
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: GSKATBKMSVEZSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20140088117A1

  公开（公告）日：2014-03-27

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I的环醚吡唑-4-基-杂环基-羧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2为环醚，X为噻唑基、吡啶基、吡啶基或嘧啶基，可用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I化合物进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病或相关病理条件的方法。
• REDOX DRUG DERIVATIVES
  申请人：Lindsay Derek

  公开号：US20120077974A1

  公开（公告）日：2012-03-29

  The present invention provides redox drug derivatives. In particular, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, (3R,4R,5S)-4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester, (3S)-3-(aminomethyl)-5-methylhexanoic acid, (3S)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-α-α-diphenyl-3-pyrrolidineacetamide, (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane-1-carboxylic acid and (2R,3R,4S)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid redox derivatives.

  本发明提供了氧化还原药物衍生物。特别是9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶[1,2,3-de]-1,4-苯并噁嗪-6-羧酸，1-乙基-6-氟-1,4-二氢-7-(4-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸，(3R,4R,5S)-4-(乙酰氨基)-5-氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯，(3S)-3-(氨甲基)-5-甲基己酸，(3S)-1-[2-(2,3-二氢-5-苯并呋喃基)乙基]-α-α-二苯基-3-吡咯烷乙酰胺，(1S,2S,3S,4R)-3-[(1S)-1-乙酰氨基-2-乙基-丁基]-4-(二氨基甲基亚氨基)-2-羟基-环戊烷-1-羧酸和(2R,3R,4S)-4-[(二氨基甲基亚氨基)氨基]-3-乙酰氨基-2-[(1R,2R)-1,2,3-三羟基丙基]-3,4-二氢-2H-吡喃-6-羧酸氧化还原衍生物。
• Opsin-Binding Ligands, Compositions and Methods of Use
  申请人：Garvey David S.

  公开号：US20140135374A1

  公开（公告）日：2014-05-15

  Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  本发明揭示了一些化合物，可用于治疗由于或与在眼中积累的有毒视觉循环产物的产生有关的眼科疾病，例如干性成人黄斑变性，以及由于或与突变的视蛋白蛋白质的错误折叠和/或视蛋白蛋白质的错误定位有关的疾病。还描述了这些化合物的组合物，单独使用或与其他治疗剂联合使用的组合物，以及使用这些化合物和/或组合物的治疗方法。还揭示了合成这些药剂的方法。
• Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use
  申请人：Genentech, Inc.

  公开号：US20160213652A1

  公开（公告）日：2016-07-28

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的环氧杂环基卡氧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2是环氧杂环基，X是噻唑基、吡嗪基、吡啶基或嘧啶基，可用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I中的化合物进行哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF
  申请人：YU Henry

  公开号：US20160152609A1

  公开（公告）日：2016-06-02

  The present invention relates to imidazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).

  本发明涉及咪唑化合物及其药学上可接受的组合物，其作为卵泡刺激素受体（FSHR）的正向变构调节剂具有用途。